GETT
19.4.2021 15:02:06 CEST | Business Wire | Press release
Gett, the leading innovator in corporate Ground Transportation Management (GTM), continues to expand its marketplace of global partner fleets onto one technology platform to provide broad geographic coverage and service levels for enterprise clients.
Gett launched one of the first-ever on-demand corporate travel services in 2010, attracting Google and Disney among its first clients. With over 10 years of expertise designing seamless ground transportation experiences, Gett reduces corporate spend on ground transportation for its clients by up to 45% by offering price comparison, enforcement of travel policy compliance and optimization of back-office processes. Gett’s platform also provides other benefits, including a seamless rider experience for employers prioritizing the safety and security of their people returning to business travel following Covid-19 lockdown.
The expansion of Gett’s global platform coincides with a new supply partnership, as US taxi and e-fleet operator Curb Mobility partners with Gett and joins a portfolio of operating fleets including Lyft and Ola to access incremental high quality demand. This partnership will enable Gett to extend its presence to 65 cities in the US, expanding Gett’s marketplace to include yellow cabs as well as Gett’s existing range of vehicles and partner fleets. Bringing corporate customers a range of licensed vehicles, this new partnership supports increased demand for ground transportation as business professionals seek enhanced safety in light of the Covid-19 pandemic with the resumption of business travel.
Partner fleets already accounted for approximately one-third of B2B rides taken on Gett in Q1 2021. With the addition of Curb, and momentum in Gett’s transition from ride-hailing to an enterprise marketplace software platform, it is expected that partner fleets will represent the majority of Gett’s B2B rides globally by the end of 2021.
Gett’s largest markets are becoming lead indicators for the ground transportation and global corporate travel industries, with the progress of Covid-19 vaccination programmes in Israel and the UK. In Q1 2021, global transactions on Gett’s platform by corporate users returned to approximately 80% of the volumes seen for the corresponding period in 2020 ahead of Covid-19 lockdown restrictions. In this time period, individual markets also experienced corporate passenger volumes in excess of 2020 peaks.
Dave Waiser, CEO and co-founder of Gett commented : “Today’s partnership cements Gett’s position as a technology platform focused on corporate Ground Transportation Management (GTM), where spend is worth $79.6B globally. In recent years, we have become the GTM category leader, serving over a quarter of Fortune 500 companies.
“Our cloud-based software aggregates existing transportation providers into a single platform, helping businesses effectively manage all of their ground transportation spend. Additionally, it can expand companies’ coverage and reach by connecting them to a global transportation grid.
“We believe that bringing corporate fleets and ride-hailing companies together on one platform, optimising the entire employee experience, from booking and riding to invoicing and analytics, saves corporations both time and money.”
Amos Tamam, CEO at Curb commented : “As cities across the U.S. prepare for the return of international travel, our partnership with Gett will create new income opportunities for local drivers and ensure Gett's business users have access to the same safe, reliable transportation options trusted by locals. By integrating with platforms like Gett, we're aiming to make taxis more ubiquitous online by opening up new digital avenues for today’s consumers and businesses to find and book taxis.”
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005037/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom